Akari Therapeutics PLC (ADR) - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
AKTX Nasdaq 8731 https://www.akaritx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Akari Therapeutics PLC (ADR)

Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics - Sep 17th, 2024 12:00 pm
Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights - Aug 19th, 2024 8:15 pm
Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy - Aug 19th, 2024 12:00 pm
Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders - Jun 5th, 2024 12:00 pm
Akari Therapeutics Secures $7.6 Million in Upsized Financing Round - Jun 4th, 2024 12:00 pm
Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights - May 16th, 2024 12:00 pm
Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics - May 1st, 2024 12:01 pm
Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity - May 1st, 2024 12:00 pm
Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024 - Apr 15th, 2024 12:00 pm
Akari Therapeutics Insider Ups Holding By 69% During Year - Apr 1st, 2024 5:13 pm
Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights - Apr 1st, 2024 10:30 am
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit - Mar 5th, 2024 1:00 pm
Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing - Jan 2nd, 2024 1:00 pm
Akari Therapeutics to Present at Biotech Showcase 2024 - Dec 14th, 2023 1:00 pm
Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of Directors - Dec 1st, 2023 1:00 pm
Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference - Nov 16th, 2023 1:00 pm
Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference - Nov 6th, 2023 1:00 pm
Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now - Oct 3rd, 2023 11:00 am
Akari Therapeutics Reports First Half 2023 Financial Results and Highlights - Sep 29th, 2023 12:00 pm
Akari Therapeutics to Present at Emerging Growth Conference - Sep 27th, 2023 12:00 pm